Blog

EnSilica (LSE:ENSI) has secured a series of new design and development agreements that expand its presence in healthcare technology while strengthening its automotive pipeline. The company has been awarded a US$1.6 million contract from a UK-listed life sciences technology group to develop and manufacture a next-generation chip for advanced analytical systems. In addition, EnSilica has entered into a fully funded US$200,000 feasibility study with a U.S. healthcare company to design a wireless biosensing and therapeutic controller ASIC. If successful, the project could lead to a larger multi-million-dollar supply agreement.

The company also reported increased demand and an extended production timeline for an existing automotive ASIC programme, now expected to run beyond 2030. This extension is projected to add more than US$4 million in additional revenue between 2026 and 2028. Management said the combination of new healthcare projects and expanded automotive commitments improves revenue visibility and supports expectations of significantly higher revenue and EBITDA in the 2026 financial year.

Despite these contract wins, the company’s outlook remains constrained by recent financial performance, including declining revenue, ongoing losses and a sharp deterioration in free cash flow. However, technical indicators provide a partial counterbalance, with the share price trading well above key moving averages and showing strong upward momentum, though some indicators suggest the rally may be approaching stretched levels. Valuation metrics remain challenging as the company is currently loss-making and does not offer a dividend yield.

More about EnSilica PLC

EnSilica plc is a fabless semiconductor company specialising in the design of application-specific integrated circuits (ASICs), including RF, millimetre-wave, mixed-signal and complex digital chips. The company serves customers across sectors such as space and communications, industrial systems, automotive and healthcare. EnSilica focuses on delivering secure and reliable semiconductor solutions and leverages reusable intellectual property and silicon platforms to support scalable design projects and long-term supply revenue streams.

Somero Enterprises (LSE:SOM), a global specialist in laser-guided concrete levelling systems and related training services, continues to support commercial construction projects through its proprietary technology and service-focused model. The company has expanded its product portfolio with electric and next-generation boomed screeds as well as ride-on machines, broadening its addressable market and strengthening its position in high-specification industrial flooring.

For 2025, Somero reported revenue of $88.9 million, representing a 19% year-on-year decline, alongside lower margins. However, the company noted a stronger performance in the second half of the year, supported by disciplined cost management and solid cash generation. New and upgraded products contributed $13 million in sales, while regional revenue trends improved significantly during the latter half of the year. Operating cash flow remained stable, enabling the group to maintain its dividend payments, carry out share buybacks and enter 2026 expecting revenue, profitability and cash generation broadly in line with the prior year.

Somero maintains a strong financial position with low levels of debt and attractive valuation metrics, while recent share buybacks have further supported shareholder returns. However, the drop in revenue and pressure on cash flow generation present risks that the company will need to address. Technical indicators currently show mixed signals, with no clear directional trend in the share price.

More about Somero Enterprises Inc

Somero Enterprises Inc designs and manufactures laser-guided concrete levelling equipment and provides associated training, education and technical support to contractors in more than 90 countries. Its technology enables faster and more precise installation of horizontal concrete floors used in a wide range of commercial developments, including facilities for major global blue-chip companies, reinforcing its long-standing leadership in the Laser Screed market.

Sabre Insurance Group (LSE:SBRE) reported a 4.9% increase in profit before tax for 2025 to £51 million, while its net insurance margin improved to 19.2%. The results came despite a 14.2% decline in gross written premiums, reflecting the company’s strategy of maintaining strict pricing discipline rather than pursuing volume growth during softer market conditions. Supported by a strong capital position, Sabre raised its total dividend for the year to 13.5p per share and announced plans for a £5 million share buyback. The company said its solvency coverage ratio will remain within the targeted 140%–160% range even after these capital returns.

Management noted that disciplined pricing, combined with easing claims inflation, helped deliver strong profitability and has positioned the group for a return to premium growth. Early trading in 2026 indicates that motor vehicle gross written premiums are already more than 5% higher year on year. Strategic initiatives under the company’s Ambition 2030 plan are also advancing, including the launch of Sabre Direct for motorcycles and the rollout of new differentiated pricing models. These initiatives are expected to support higher profitability and sustainable growth over the coming years.

The company’s outlook is supported by strong financial fundamentals, including a robust balance sheet with low leverage and an attractive valuation profile marked by a relatively low price-to-earnings ratio and a high dividend yield. Technical indicators are moderately positive but mixed when compared with longer-term averages. Recent corporate actions, including the announced share buyback and insider share purchases, also provide supportive signals for investors.

More about Sabre Insurance Group plc

Sabre Insurance Group plc is one of the UK’s leading specialist motor insurance underwriters, offering policies for cars, motorcycles and taxis. The company focuses on disciplined underwriting, careful management of insurance cycles and conservative assumptions around claims inflation, allowing it to maintain strong margins and capital resilience in the competitive UK motor insurance market.

Rotork (LSE:ROR) reported solid results for 2025, with order intake increasing 6.0% on an organic constant-currency basis and revenue rising 3.7%. Growth was supported by strong performance in the Chemical, Process & Industrial (CPI) and Water & Power segments, as well as continued momentum from the Rotork Service division. This progress came despite some project delays affecting the midstream Oil & Gas market. Adjusted operating profit increased 10% on the same basis, while operating margins expanded to 24.6% and return on capital employed reached 38.4%.

During the year, the group deployed capital through the acquisition of Noah, the disposal of non-core assets, and a £100 million share buyback programme. Rotork also maintained a net cash position and increased its full-year dividend by 7.1%, reflecting management’s confidence in continued progress through 2026 as its Growth+ strategy advances.

The company’s outlook is primarily supported by strong financial performance, including healthy revenue and cash flow growth, low leverage and efficient use of equity capital. However, technical indicators suggest the possibility of near-term share price weakness, and the company’s relatively high price-to-earnings ratio raises questions about valuation, moderating the overall investment outlook.

More about Rotork plc

Rotork plc is a UK-based engineering group specialising in flow control and instrumentation technologies used across the Oil & Gas, Chemical, Process & Industrial (CPI), and Water & Power sectors. The company designs and manufactures actuators, control systems and related services, with an increasing emphasis on electric actuation and aftermarket support. This strategy positions Rotork as an asset-light, high-margin supplier serving critical infrastructure industries worldwide.

Spirax Group (LSE:SPX) reported organic revenue growth of 5% to £1.70 billion in 2025, outperforming global industrial production levels. All three of the company’s divisions recorded organic sales increases, while improved adjusted margins helped lift the group’s organic adjusted operating margin to 20%. However, statutory profit declined during the period as one-off restructuring costs weighed on reported operating profit and margins. Despite this, Spirax improved cash conversion, reduced leverage to 1.5 times EBITDA, increased returns on capital, and raised its dividend.

Performance across divisions was mixed. Steam Thermal Solutions recorded modest organic growth but experienced pressure on statutory margins. Electric Thermal Solutions achieved double-digit organic revenue growth, supported in part by recovering semiconductor demand, while Watson-Marlow delivered mid-single-digit growth as activity in biopharma markets strengthened. Management said a recently completed efficiency and simplification programme is now generating around £40 million in annualised cost savings, providing additional capacity for reinvestment and supporting expectations of further organic growth and margin expansion in 2026 despite ongoing macroeconomic uncertainty.

The company’s outlook is supported by strong financial performance and positive commentary from its latest earnings call. Technical indicators suggest a largely neutral share price trend, while valuation metrics imply the stock may be trading at elevated levels. Management believes its ongoing strategic initiatives and restructuring programme will support long-term performance, even as certain regional markets remain challenging.

More about Spirax Group

Spirax Group is a UK-based engineering company specialising in thermal energy and fluid technology solutions that help industrial customers improve efficiency, safety and decarbonisation. The group operates through three main divisions: Steam Thermal Solutions, Electric Thermal Solutions and Watson-Marlow Fluid Technology Solutions. Its technologies serve industries including food processing, healthcare, semiconductors and biopharmaceuticals, with more than 30 manufacturing sites and over 100,000 customers worldwide.

Nuformix (LSE:NFX) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for tranilast lystate, the inhaled active compound used in its NXP002 programme for idiopathic pulmonary fibrosis (IPF), a rare and often fatal lung disease. The designation follows a similar orphan status previously awarded in Europe and provides several development incentives, including potential tax credits, reduced regulatory fees and the possibility of market exclusivity. Nuformix said the recognition could strengthen its position in ongoing licensing discussions and increase the strategic value of the NXP002 programme for potential partners.

With orphan designation now secured in both the United States and Europe, Nuformix is further establishing its presence in the specialised fibrosis treatment space. The regulatory support could help accelerate progress toward future clinical and commercial milestones. The company said the achievement also demonstrates the potential of its drug repurposing approach to generate regulatory assets that may attract partnerships and support longer-term value creation, although the programme remains at a preclinical stage.

The company’s broader outlook remains constrained by weak financial performance, including the absence of recent revenue, continuing losses and sustained negative free cash flow, though it operates without debt. Technical indicators also suggest downside pressure, with the share price trading below key short- and medium-term averages and a negative MACD signal. Valuation metrics are similarly limited by negative earnings and the lack of dividend support.

More about Nuformix Plc

Nuformix plc is a UK-listed pharmaceutical development company focused on treating unmet medical needs in fibrosis and oncology through drug repurposing. The company specialises in identifying, developing and patenting improved forms of existing drugs with enhanced physical properties, creating differentiated products with new commercial opportunities and early-stage licensing potential from its pipeline of preclinical assets.

Concurrent Technologies (LSE:CNC) has introduced a new lineup of rugged embedded computing cards built on Intel’s latest Core Ultra Processor (Series 3) architecture. The products are aimed at demanding applications across defence, aerospace, critical infrastructure and industrial sectors, where they are designed to support mission computing, sensor processing, AI-enabled edge analytics and high-speed data management in long-life platforms.

The product family includes the Eir 3U OpenVPX processor board developed for next-generation VPX-based systems, along with the Hermes II and Magni II SOSA-aligned 3U VPX cards designed to handle data-intensive workloads and AI-driven processing. Also included is Caelus, a next-generation VME processor card created to extend the operational life of legacy systems through at least 2035. The Hermes II and Magni II platforms incorporate hardware-based secure enclaves, addressing strict security requirements common in defence and aerospace deployments.

By launching the new cards alongside Intel’s Panther Lake platform, Concurrent Technologies demonstrates its ability to rapidly adopt and deploy next-generation processor technologies. The simultaneous release of several boards also expands the company’s SOSA-aligned VPX portfolio. Management said the approach reflects an accelerated innovation cycle intended to provide customers with clearer upgrade paths, extended lifecycle support and enhanced hardware security while supporting the group’s longer-term revenue growth plans.

The company’s outlook is supported by strong financial performance, including solid growth in revenue and cash flow. However, technical indicators currently suggest bearish market momentum, while the relatively high price-to-earnings ratio raises valuation concerns. Recent corporate developments have also presented mixed signals, including a positive defence contract offset by potential negative sentiment following a share sale by the chief executive.

More about Concurrent Technologies

Concurrent Technologies Plc is a UK-based designer and manufacturer of high-performance embedded plug-in computer cards and systems used in long-life, mission-critical applications. Its products, primarily based on Intel processors, serve global markets including telecommunications, defence, security, telemetry, scientific research and aerospace, often in environments with extreme operating conditions.

The company specialises in standards-compliant hardware compatible with leading embedded operating systems and industry specifications. Its portfolio includes solutions based on Intel Core, Xeon and Atom processors, engineered to support demanding workloads that require reliability, ruggedisation and long-term lifecycle support.

Ferro-Alloy Resources (LSE:FAR) has raised £1.57 million through the issuance of 28.6 million new ordinary shares priced at 5.5p each, representing a 21.4% discount to the company’s previous closing share price. The funds will be used to support front-end engineering and design activities for the Balasausqandiq vanadium project in Kazakhstan. Existing strategic investor Vision Blue Resources participated in the placing as a related party, increasing its holding to around 22.5% of the company’s enlarged share capital. The newly issued shares are expected to commence trading in London on 13 March 2026, bringing the company’s total issued share count to approximately 587.8 million.

Despite the capital raise, the company’s outlook continues to be weighed down by weak financial performance, including ongoing losses, negative cash flow, and negative equity. Technical indicators provide some positive signals, with the share price trading above key moving averages and showing strong momentum, although overbought conditions may pose short-term risks. Valuation metrics remain limited given the company’s loss-making position and the absence of dividend support.

More about Ferro-Alloy Resources Ltd.

Ferro-Alloy Resources Limited is a vanadium producer focused on advancing the large Balasausqandiq deposit in southern Kazakhstan. At the project, vanadium is expected to be the primary product, alongside a carbon black substitute and several additional by-products. The company operates a concentrate processing plant and research and development facility at the site, aiming to leverage relatively low capital and operating costs to compete in global vanadium and carbon materials markets.

Pennon Group (LSE:PNN) said EBITDA for the period to 9 March 2026 rose by roughly 55% year on year, with underlying profitability for the 2025/26 financial year expected to meet market forecasts, albeit toward the lower end of expectations. The company noted that operational performance has been affected by unusually heavy rainfall and storm-related power outages, factors that are likely to result in a net Outcome Delivery Incentive (ODI) penalty across its water and wastewater services.

Despite the challenging weather conditions, the group reported significant improvements in environmental performance. Wastewater pollution incidents have declined by about 40%, while normalised pollution levels have fallen 55% and storm overflow usage is down 17%. Pennon said these improvements reflect substantial investment in network infrastructure. Water quality metrics remain strong, with the company delivering upper-quartile performance, while early-stage work on its AMP8 capital investment programme is progressing as planned and supported by solid liquidity and balance sheet strength.

The company is also continuing to address regulatory investigations related to historical wastewater pollution events and a water quality incident that occurred in 2024. Pennon expects these matters to conclude during 2026. At the same time, the group is expanding its renewable energy initiatives through the Pennon Power portfolio. Two of the four planned sites are now operational, and the full portfolio is projected to generate energy equivalent to around 40% of the company’s consumption by the 2027 financial year.

A leadership transition is also underway, with Keith Haslett set to take over as chief executive officer on 1 April 2026. Pennon reiterated that its largest capital investment programme to date remains fully funded and is designed to deliver operational efficiencies, strengthen asset resilience, and generate returns on capital during the K8 regulatory period despite ongoing regulatory scrutiny and operational challenges.

The company’s outlook reflects a combination of positive operational progress and ongoing pressures. Revenue growth has been encouraging, but concerns remain around profitability and leverage levels. Technical indicators currently show positive market momentum, while the relatively high price-to-earnings ratio suggests the stock may be trading at elevated valuation levels. Management believes continued operational improvements and strategic investments will support longer-term performance.

More about Pennon Group plc

Pennon Group plc is a UK-based provider of water and wastewater services, operating primarily through South West Water and SES Water. The company supplies regulated utility services across South West England and other regions while expanding into renewable energy generation through its Pennon Power portfolio to help meet its operational energy requirements.

Tap Global Group plc (LSE:TAP), a digital finance platform that combines traditional payment services with cryptocurrency trading and settlement, serves more than 400,000 customers across Europe, the United States, and other international markets. Through its mobile app and Mastercard-linked payment card, users can buy, store, and spend digital assets, supported by AI-driven pricing technology and a regulated operational structure spanning Gibraltar, Bulgaria, and the U.S.

The company has acquired three billion XTP tokens from related party Tap N Go Ltd at no cost. The holding is valued at approximately US$1.8 million and represents around 30% of the token’s total supply. Management intends to use the token reserve to support cashback and loyalty programmes, user acquisition initiatives, trading promotions, and referral incentives. The transaction creates one of the largest token treasuries among AIM-listed companies and strengthens Tap’s balance sheet while aligning the group more closely with the XTP ecosystem.

Independent directors, with guidance from the company’s nominated adviser, determined that the related-party transaction is fair and reasonable for shareholders. Chief executive and major shareholder Arsen Torosian said the move supports Tap’s strategy to accelerate user growth and platform engagement. By further integrating the XTP token into its platform, the company aims to increase card usage, boost trading activity, and support the long-term development of its ecosystem as it works toward its goal of becoming a leading “crypto bank.”

More about Tap Global Group plc

Tap Global Group plc is a digital finance platform that integrates fiat payment services with cryptocurrency trading and settlement through a single application. The company provides access to more than 50 cryptocurrencies and offers real-time best execution through proprietary AI middleware. Its Mastercard-linked card enables European customers to spend converted digital assets at millions of merchants worldwide.

The group operates through regulated subsidiaries in Gibraltar, Bulgaria, and the United States, positioning itself as a bridge between traditional financial services and blockchain-based technology. Its European business was the first cryptocurrency fintech approved by Mastercard in the region, while its U.S. operations rely on third-party crypto infrastructure as part of a strategy focused on regulatory compliance and international expansion.